IPHA.US Innate Pharma

Healthcare Biotechnology USA Stocks
1.38 USD
Close of Nov 15, 2026
1.17 2.71
Market cap
USD 154M
P/E
-
P/B
30.69x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is IPHA.US undervalued?

Graham number

The Graham number of Innate Pharma cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Innate Pharma fundamental analysis

No fundamental analysis for Innate Pharma yet.

Innate Pharma stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that…

Full company profile